Equity Field Notes from temporal sources

[DanWebzster]

MNOV read out positive Ph2B data in progressive MS during 4/18

This is significant because there is presently only treatment for Progressive MS. 85% of the overall MS patient population suffere from relapsing-remitting MS (RRMS)

Roche produces the only approved treatment for Progressive MS. This Ph2B study showed MNOVs compound to be superior to Roche's compound in slowing the time to confirmed disability.

MNOV used this data as an opty to raise $40mn. It now has a runway until Q4/2019.

MNOV also has ongoing clinical programs in NASH & ALS.